Eosinophil Count

For the total trial population, only the eosinophil count median changed in the correction; the observed range remained 60–20,910 cells. The baseline median eosinophil count for the total trial population was corrected from 1,120.0 to 1,100.0 cells, with the observed range unchanged. The baseline median eosinophil count in the benralizumab group was corrected from 1,070.0 cells (range 230–5,620) to 1,085.0 cells (range 360–5,620). The baseline median eosinophil count in the benralizumab group was corrected from 1,070.0 to 1,085.0 cells, and the lower range boundary changed from 230 to 360 cells. The baseline median eosinophil count for the total trial population was corrected from 1,120.0 to 1,100.0 cells, while the observed range remained unchanged. The corrected baseline median eosinophil count for the benralizumab group is 1,085.0 cells with a range of 360–5,620. The corrected total-population median eosinophil count (1,100.0 cells) is lower than the originally reported value (1,120.0 cells), while the range remained unchanged. The baseline median eosinophil count in the benralizumab group was corrected from 1,070.0 to 1,085.0 cells, with the lower range bound raised from 230 t…